Format

Send to

Choose Destination
Int J Biochem Cell Biol. 2009 Apr;41(4):729-32. doi: 10.1016/j.biocel.2008.04.028. Epub 2008 Aug 13.

CCL2 DNA vaccine to treat renal disease.

Author information

1
Centre for Kidney Research, Children's Hospital at Westmead, Westmead, New South Wales, Australia.

Abstract

CCL2 DNA vaccines are directed against the host chemoattractant molecule CCL2 (MCP-1), a key chemokine in recruiting macrophages to sites of inflammation. Macrophages recruited by CCL2 lead to progressive renal injury. In rat models of disease unmodified CCL2 DNA vaccine in combination with a CCL5 (RANTES) DNA vaccine can protect against chronic renal disease. The mechanism of protection involves the induction of auto-antibodies to the CCL2. Introduction of the adjuvant p-tet into the DNA structure of the CCL2 vaccine leads to enhanced potency with the induction of specific Th1 cellular immunity. The strategies outlined here demonstrate a model for developing potent vaccines against highly restricted self targets.

PMID:
18768165
DOI:
10.1016/j.biocel.2008.04.028
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center